Recent developments
AI in R&D
Pharma and specialty chemicals advanced AI-enabled discovery and development. Novo Nordisk announced a strategic partnership with OpenAI to apply AI across discovery, manufacturing, and supply chain. BASF launched biotech cosmetic actives discovered and scaled using Bota Biosciences' SAION AI platform. CDMO capabilities emphasized digital execution, with AGC Pharma Chemicals recognized for effective Technology Use. Patient-centric delivery added data layers as Aptar Digital Health became Enable Injections’ preferred digital partner to build a companion solution for the enFuse system.
Connected operations
Upstream operators expanded sensorization and analytics. Petrobras began deploying a permanent reservoir monitoring seabed sensor network at Mero, pairing UFRJ collaborations to apply AI on continuous seismic data. Tengizchevroil scaled plant digital twins, private LTE, and IoT to improve safety and turnaround controls. In refining, Honeywell will deliver Performance+ services and the Honeywell Forge platform at Dangote, alongside Operator Training Simulators built from digital twins.
Advanced process control
Large capital projects integrated advanced automation and modeling. NextDecade’s Rio Grande LNG expansion selected Honeywell’s C3MR liquefaction process to enhance reliability and enable software-driven optimization. Steelmaking modernization at POSCO Pohang will use EnviBAT single‑chamber pressure regulation in a new low‑emission coke oven battery. High‑sulfur gas management incorporated multi‑component, multi‑field coupled numerical simulation models in Zhongyuan Oilfield’s CCUS‑EGR pilot.
Low‑carbon initiatives
Low‑carbon fuels progressed to bankability and traceability. Southern Energy Renewables and Axens signed an MoU on biomass‑to‑fuels in Louisiana and introduced an experimental digital token, $SAF to link production data with issuance and retirement events without changing commercialization.
Supply and delivery
Regulatory allowances affected cold-chain design. The EMA’s approval for controlled‑temperature delivery up to 48 hours for Wegovy injection reduces final‑mile constraints and packaging loads, simplifying direct‑to‑patient distribution models.